Coenzyme Q10 (Ubiquinone / Ubiquinol)
Coenzyme Q10 (CoQ10) is a vitamin-like substance the body makes for itself and that is found in every cell, where it helps turn food into the energy cells run on. Levels fall naturally with age and are lowered by statin medicines. It is sold as a food supplement, most often in oil-filled soft-gel capsules. There is no UK-authorised health claim for CoQ10: this page describes what it is, what people take it for, and what the UK guidance and the evidence actually say.
Camden Medicals editorial · Last reviewed 11 June 2026 · Next review June 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Other
- Typical daily dose
- UK retail products supply 30–300 mg of CoQ10 per serving. Heart-failure adjunct trials have used 100 mg three times daily (Q-SYMBIO). General-supplementation context: 100–200 mg/day in lipid-carrier soft-gels with a meal. Splitting doses (50–100 mg twice daily) raises plasma levels more efficiently than a single high dose.
- Top use evidence
- Moderate
On this page
What it is
Coenzyme Q10 (CoQ10), also called ubiquinone-10, is a small fat-soluble quinone with a benzoquinone head group and a 10-isoprene side chain. It is present in the inner mitochondrial membrane of every human cell, where it functions as a mobile electron carrier between Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase) of the electron-transport chain on one side, and Complex III (cytochrome bc1) on the other. Without CoQ10, Complex IV (cytochrome c oxidase) cannot receive the electrons needed to reduce molecular oxygen to water, ATP synthesis collapses, and the cell dies. CoQ10 is therefore essential to mitochondrial energy metabolism in every tissue but particularly the heart, skeletal muscle, liver, and brain — tissues with high mitochondrial density.
CoQ10 is endogenously synthesised via the mevalonate pathway — the same biosynthetic pathway that produces cholesterol. Statin drugs (atorvastatin, simvastatin, rosuvastatin, pravastatin) inhibit HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway, which suppresses both cholesterol biosynthesis AND CoQ10 biosynthesis. Statin therapy has been documented to reduce circulating CoQ10 by approximately 30–50%. Whether this contributes mechanistically to statin-associated muscle symptoms (myalgia, myopathy, rare rhabdomyolysis) is a long-running debate. UK NICE statin guidance (NG238 lipid modification) does NOT list CoQ10 supplementation as a management pathway for statin-associated muscle symptoms.
Two principal commercial forms exist. Ubiquinone is the oxidised form, the conventional supplement form, lower cost, and adequate for most adults under about 50 with normal endogenous reduction capacity. Ubiquinol is the reduced form (one mole of CoQ10 cycles between ubiquinone and ubiquinol every ~2.4 minutes during electron transport in healthy tissue); after about age 50 the body's reduction capacity declines, and supplementing the already-reduced ubiquinol form is the rational choice. KanekaQH (Kaneka Corporation, Japan) is the principal branded ubiquinol ingredient, licensed through distributors to finished-product manufacturers; Bio-Quinone (Pharma Nord) is the principal branded ubiquinone form with a long Scandinavian clinical research portfolio. Both forms require a lipid carrier (sunflower oil, MCT, rice bran oil) for absorption — dry powder CoQ10 has poor bioavailability and is the principal red flag in commercial labelling.
Regulatory note: CoQ10 is a lawful UK food supplement. There are no authorised UK food-supplement health claims for CoQ10 — the EFSA NDA opinions on health-claim applications submitted under EU Regulation 1924/2006 were unfavourable, and the on-hold list does not include CoQ10 today. Cardiovascular and lifespan-marketing framing on UK food-supplement labels is not permissible.
At a glance
- A vitamin-like substance the body makes for itself, found in every cell, where it helps release energy. Levels fall with age and on statin medicines.
- No UK-authorised health claim. EFSA assessed the CoQ10 health-claim applications and did not substantiate them; the GB health-claims register lists no authorised CoQ10 claim.
- Sold in two forms — ubiquinone and ubiquinol — usually in oil-filled soft-gels, because CoQ10 needs some dietary fat to be absorbed.
- It can interact with warfarin and similar blood thinners. If you take anticoagulants, a statin, blood-pressure medicines, or are pregnant, talk to your pharmacist or GP first.
What people use it for
Adults aged 50+ exploring antioxidant supplementation alongside diet and lifestyle measures
CoQ10 is made by the body, but circulating levels decline with age. A supplement at 100–200 mg/day in oil-filled capsules raises plasma levels reliably. The UK food-supplement claim space is empty (no authorised health claim), so any use is descriptive rather than claim-led. Talk to your GP or pharmacist if you take prescription medication.
Popular, not provenInsufficientAdults on statin therapy with statin-associated muscle symptoms (myalgia)
CoQ10 is widely discussed online for statin-related muscle aches; the current evidence does not support this use. UK NICE NG238 (lipid modification) does not list CoQ10 as a management step, and the British Heart Foundation states current evidence does not support taking CoQ10 for statin-attributed muscle pain. The recognised UK steps are reducing the statin dose, switching statin, or alternate-day dosing under prescriber oversight. Talk to your prescriber. [1]
Not supportedMixedAdults with heart failure considering CoQ10 alongside standard treatment
The Q-SYMBIO trial (Mortensen et al. 2014) reported fewer major adverse cardiovascular events on CoQ10 100 mg three times daily added to standard heart-failure therapy in 420 patients. Cochrane and later pooled analyses are more conservative — mortality signals do not consistently reach significance. UK NICE NG106 and the ESC heart-failure guideline list the recommended therapies and do not include CoQ10. This is a discussion to have with a cardiologist, not a self-supplement decision. [4]
Popular, not provenMixedPeople with primary CoQ10 deficiency (a rare inherited mitochondrial condition)
Primary CoQ10 deficiency is a hospital-led metabolic-disease diagnosis managed with high-dose oral CoQ10 (often 5–30 mg/kg/day) under specialist care — it is the mitochondrial disorder most responsive to CoQ10, though the response varies by genotype and organ (renal and metabolic features often improve; neurological involvement frequently does not). This is a specialist context, not a self-supplement one. [10,11]
Some evidenceModerate
How it works
The electron-transport chain mechanism is direct: NADH and FADH2 produced by glycolysis, fatty-acid β-oxidation, and the citric-acid cycle donate electrons to Complex I and Complex II respectively; those electrons reduce CoQ10 to ubiquinol, which diffuses through the membrane to Complex III, where the electrons are passed to cytochrome c, then to Complex IV, where molecular oxygen is reduced to water. The proton gradient generated drives ATP synthase (Complex V). CoQ10's 10-isoprene tail anchors it in the lipid bilayer; its head group cycles between oxidised and reduced states. Without adequate CoQ10, all downstream ATP synthesis from aerobic respiration is impaired.
The lipid-phase antioxidant role is secondary but mechanistically relevant — ubiquinol can quench peroxyl radicals in lipoprotein particles (LDL especially) and regenerate vitamin E (alpha- tocopheryl radical → alpha-tocopherol). This is the basis of the CoQ10-LDL-oxidation literature, although translating this to cardiovascular outcome benefit has not been demonstrated in pivotal trials.
Statin-induced CoQ10 depletion is mechanistically expected: HMG-CoA reductase produces mevalonate, which feeds both cholesterol biosynthesis and the prenyl-pyrophosphate pool that produces the 10-isoprene tail of CoQ10. Statin inhibition reduces both. Whether correcting the CoQ10 reduction with supplementation alters the incidence of statin-associated muscle symptoms is what the trial literature has tested with mixed conclusions.
Common myths
Myth""Higher dose CoQ10 is always better""
RealityAbsorption saturates around 200 mg taken in a single dose (lipid-carrier formulations push the ceiling slightly higher). Splitting doses (e.g. 100 mg twice daily) raises plasma levels more efficiently than 300 mg in one dose. Doses above 600 mg/day are uncommon in general supplementation; very high doses (above 1.2 g/day) have been used in primary CoQ10 deficiency and some Parkinson''s trials but are not a general-supplementation context.
Myth""CoQ10 reverses ageing""
RealityAgeing is a complex multi-factor process; supplementation with any single nutrient does not reverse it. CoQ10 supplementation raises plasma CoQ10 reliably and corrects the age-related decline in circulating levels — that is a description of biochemical state, not a reversal of ageing itself. UK food- supplement claims for lifespan or ageing-reversal are not permissible.
Myth""Ubiquinol is dramatically more bioavailable than ubiquinone for everyone""
RealityFor adults under about 50 with normal endogenous reduction capacity, ubiquinone is adequate and the body reduces it readily. Ubiquinol''s practical advantage is for adults over 50 (when reduction capacity declines) or on statin therapy (where the entire mevalonate pathway is suppressed). Younger adults paying the ubiquinol price premium without that rationale are paying for marketing.
Myth""CoQ10 is a substitute for statin therapy""
RealityIt is not. Statins reduce LDL cholesterol via direct enzyme inhibition; CoQ10 has no comparable effect on serum lipids. UK NICE NG238 lists statin therapy as the primary pharmacological intervention for elevated cardiovascular risk; CoQ10 is not on those pathways. Anyone considering stopping prescribed statin therapy must do so only under prescriber review. [1]
Myth""Dry-powder CoQ10 tablets work the same as oil-suspended soft-gels""
RealityThey do not. Dry-powder CoQ10 has poor oral bioavailability — the molecule needs dietary fat for absorption. Soft-gel capsules dissolved in sunflower oil, MCT, or rice bran oil deliver the active reliably; dry-powder tablets are the principal red flag in commercial labelling regardless of label dose.
Common online questions
Synthesised from the questions UK shoppers most often ask online about Coenzyme Q10 (Ubiquinone / Ubiquinol). Each answer is editorial and links to its evidence in the Sources list below.
What is the difference between ubiquinone and ubiquinol?
Both are CoQ10. Ubiquinone is the oxidised form — the conventional supplement form, lower cost, and the form most trials have used historically. Ubiquinol is the reduced form — the form actively circulating in plasma after about age 50, when the body''s reduction capacity declines. For adults under 50, ubiquinone is adequate and the body reduces it readily. For adults over 50 or on statin therapy, ubiquinol is the rational choice because it is supplied in the already-active form. KanekaQH (Kaneka, Japan) is the principal branded ubiquinol ingredient.
Should I take CoQ10 if I am on a statin?
Talk to your prescriber. Statins suppress endogenous CoQ10 biosynthesis by ~30–50% via the shared mevalonate pathway, and whether this contributes to statin-associated muscle symptoms is a long-running debate. UK NICE NG238 (lipid modification) does not list CoQ10 supplementation as a recognised pathway for managing statin-associated muscle symptoms — the recognised steps are statin dose reduction, rotation, alternate-day dosing, or switching agents under prescriber oversight. Self-supplementation in place of prescriber review is not appropriate. [1]
Why does CoQ10 need a lipid carrier?
CoQ10 is fat-soluble; like vitamin K and vitamin E, it needs dietary fat for absorption. Dry-powder CoQ10 in a tablet is the principal red flag in commercial labelling — bioavailability is poor. Soft-gel capsules dissolved in sunflower oil, MCT, or rice bran oil deliver the active reliably. Take with a meal containing some fat for further bioavailability gains.
Can I take CoQ10 with my warfarin?
Talk to your prescriber. CoQ10 has been documented to reduce INR in warfarin-anticoagulated patients in case reports — the mechanism is the structural similarity between the CoQ10 benzoquinone head group and vitamin K. Co-monitoring of INR when starting or changing CoQ10 dose is appropriate. If you take warfarin, your pharmacist or GP can check interactions and arrange INR monitoring; the UK BNF is the reference clinicians use for this. [8]
Does CoQ10 prevent heart disease?
No UK-authorised food-supplement health claim for CoQ10 covers cardiovascular disease prevention. The Q-SYMBIO trial in chronic heart failure reported some benefit; pivotal cardiovascular- prevention trials have not been done. UK NICE pathways for cardiovascular risk reduction (lipid management, blood pressure management, lifestyle measures) do not include CoQ10. Marketing framing CoQ10 as cardiovascular protection is not permissible on UK food-supplement labels.
Can I take CoQ10 in pregnancy?
Defer. There is limited human pregnancy safety data for supplementation at standard doses. Talk to your midwife or GP before continuing CoQ10 if you become pregnant.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Heart failure (HFrEF) — adjunct to standard therapy
MixedEvidencemixedThe Q-SYMBIO trial (Mortensen 2014) reported reduced major adverse cardiovascular events at 100 mg three times daily over 2 years in 420 patients with chronic heart failure. Cochrane systematic reviews report inconsistent mortality and quality- of-life benefits when smaller trials are pooled. UK NICE NG106 does not list CoQ10 as a recommended adjunct. Effect sizes plausible but not confirmed at the pivotal-trial level. [4,12]
Statin-associated muscle symptoms (myalgia)
MixedEvidencemixedTrials of CoQ10 100–200 mg/day in statin-associated muscle symptoms have reported variable benefit. Meta-analyses report small reductions in muscle-pain scores in some pooled analyses, no benefit in others. UK NICE NG238 does not list CoQ10 supplementation in the statin-myopathy management pathway — recommended steps are dose reduction, statin rotation, alternate-day dosing, or switching agents. [1]
Migraine prophylaxis
LimitedEvidencelimitedSmall trials of CoQ10 100–300 mg/day for migraine prophylaxis in adults reported modest reductions in headache frequency. UK NICE CG150 lists first-line migraine prophylaxis options (propranolol, topiramate); CoQ10 is mentioned in some secondary literature but is not a UK NICE-listed first-line option. Self-supplementation in place of GP review is not appropriate. [7]
Female fertility (oocyte quality in advanced maternal age)
LimitedEvidencelimitedSmall trials of CoQ10 supplementation (typically 200–600 mg/day) in women undergoing IVF have reported some improvements in oocyte yield and embryo quality scores. UK NICE CG156 (fertility problems: assessment and treatment) does not list CoQ10 as a recommended adjunct. This is a discussion to have with your fertility specialist, not a self-supplement decision. [6]
Blood pressure reduction (mild hypertension)
LimitedEvidencelimitedSome meta-analyses of small trials report modest systolic blood-pressure reductions of 5–10 mmHg with CoQ10 supplementation. Individual trials are small and short. UK NICE NG136 (hypertension management) does not list CoQ10 as a recommended antihypertensive adjunct. [5]
Safety
CoQ10 is generally well-tolerated in healthy adults at standard supplement doses. The principal interaction risk is with warfarin and other vitamin-K-antagonist anticoagulants — talk to your prescriber. Pregnancy and breastfeeding: defer (insufficient data). Adults on statin therapy with muscle symptoms should follow NICE NG238 guidance, not self-supplement.
Talk to your pharmacist or GP first if you:
- You take warfarin or any vitamin-K-antagonist anticoagulant — case reports of reduced INR; co-monitoring is appropriate.
- You take any direct oral anticoagulant (DOAC) — limited data on the interaction; talk to your prescriber.
- You take antihypertensive medication — modest blood-pressure-lowering effects in some trials; co-monitoring is prudent.
- You take statin therapy and have new-onset muscle symptoms — follow UK NICE NG238 guidance with your prescriber rather than self-supplementing.
- You are pregnant, breastfeeding, or trying to conceive — defer.
- You have heart failure — talk to your cardiologist; this is a clinical-management decision.
Common side effects: Generally none at standard food-supplement doses. GI upset (mild nausea, abdominal discomfort) occasionally reported; mitigated by taking with food.
Pregnancy and breastfeeding
Pregnancy: defer (insufficient human safety data at supplementation doses). Talk to your midwife or GP before continuing CoQ10 if you become pregnant.
Lactation: defer (insufficient human safety data).
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- No absolute contraindications at general-supplementation doses. Specialist context for primary CoQ10 deficiency, heart failure, and fertility supplementation.
Drug interactions
- Warfarin (and other vitamin-K-antagonist anticoagulants) — case reports of reduced INR; co-monitoring is appropriate.
- Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban) — limited interaction data; talk to your prescriber before adding.
- Antihypertensives — possible additive blood-pressure-lowering effect; co-monitoring is prudent.
- Chemotherapy — mixed evidence on whether antioxidant supplementation interferes with treatment; defer to oncologist.
- Beta-blockers — case reports of reduced fatigue when CoQ10 added; not a recommended pathway, but worth flagging to prescriber.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Generally none at standard food-supplement doses (100–200 mg/day).
- GI upset — mild nausea, abdominal discomfort. Reduced by taking with a meal.
Rare side effects
- Insomnia / sleep disturbance — case reports at high doses.
- Skin rash or hypersensitivity — uncommon.
- Headache — occasionally reported.
How to take it
- Typical supplemental range
- UK retail products supply 30–300 mg of CoQ10 per serving. Heart-failure adjunct trials have used 100 mg three times daily (Q-SYMBIO). General-supplementation context: 100–200 mg/day in lipid-carrier soft-gels with a meal. Splitting doses (50–100 mg twice daily) raises plasma levels more efficiently than a single high dose.
- Timing
- With a meal containing some fat for absorption. Splitting doses (morning + evening) raises plasma levels more efficiently than single high doses.
How to spot quality
Look for
- Form named explicitly on the label — ubiquinone (oxidised) or ubiquinol (reduced).
- Lipid-carrier formulation declared — sunflower oil, MCT (medium-chain triglyceride), rice bran oil, or olive oil. Soft-gel capsule preferred over dry-powder tablet.
- KanekaQH branded ubiquinol or Bio-Quinone branded ubiquinone for documented sourcing chain.
- Dose declared in mg per serving and per capsule.
- GMP-certified manufacture; reputable supplier chain.
- CoA available on request; assay confirms identity (HPLC).
- For ubiquinol: appropriate cold-chain handling (ubiquinol is the less-stable form).
- Excipient list disclosed.
Red flags
- Form not declared — "CoQ10 100 mg" without specifying ubiquinone or ubiquinol.
- Dry-powder tablet form (poor oral bioavailability without dietary fat).
- No lipid-carrier declaration.
- Cardiovascular protection / heart-disease prevention claims (no authorised UK claim).
- Lifespan-extension or ageing-reversal claims.
- Statin-substitution claims.
- Doses above 1 g per serving in a general-supplementation context (without a primary-deficiency or trial-protocol rationale).
- Marketing that frames ubiquinol as universally better than ubiquinone without the over-50 / on-statin context.
Where Camden lands · gap declared
Camden has no Coenzyme Q10 SKU at the time of writing. CoQ10 is an Aurifera-tier candidate active per the 2026-05-10 -fera tier rule (named licensed clinical-grade ingredient on label) — a future SKU formulated with KanekaQH ubiquinol in a lipid-carrier soft-gel would qualify for Aurifera branding. The encyclopaedia entry establishes Camden''s editorial authority on CoQ10 ahead of any commercial decision. No PDP claims would be made beyond the descriptive scope of this entry; UK food-supplement claim space for CoQ10 is empty.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Alpha Lipoic Acid (ALA / thioctic acid)
Limited evidenceMitochondrial cofactor cluster — commonly stacked in mitochondrial-support formulations targeted at age-50+ consumers. Both ingredients have independent supplementation rationale and no UK-authorised co-claim.
Both contribute to mitochondrial energy metabolism via different mechanisms — CoQ10 in the electron-transport chain (Complex I/II → Complex III electron shuttle), alpha-lipoic acid as a cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase (citric acid cycle entry points). The combination is mechanistically additive in narrative terms; trial-level evidence for the combination outperforming either alone in general- supplementation context is limited.
Evidence: Both ingredients individually have small short-trial bodies of evidence in their own right. The combination is mechanistically rational but pivotal-trial evidence is absent.
Doses studied: CoQ10 100 mg + alpha-lipoic acid 200–600 mg per serving in mitochondrial-support formulations.
Vitamin E (alpha-tocopherol)
Limited evidenceLipid-phase antioxidant pair — ubiquinol regenerates the alpha-tocopheryl radical back to alpha-tocopherol, sustaining vitamin E's LDL-particle protection. Combination is mechanistically rational but no UK-authorised co-claim.
In lipoprotein particles, alpha-tocopherol (vitamin E) quenches lipid peroxyl radicals and is itself oxidised to the alpha- tocopheryl radical. Ubiquinol can reduce the alpha-tocopheryl radical back to alpha-tocopherol, sustaining its antioxidant capacity. The combination has been studied in LDL-oxidation contexts; cardiovascular outcome benefit has not been demonstrated.
Evidence: Mechanism is well-characterised; clinical-outcome benefit from the combination is not established.
Doses studied: CoQ10 100 mg + vitamin E 100–200 IU per serving in lipid-antioxidant formulations.
NMN (β-Nicotinamide Mononucleotide)
Insufficient evidenceMitochondrial / NAD+ axis — different mechanism but commonly stacked in mitochondrial-support formulations targeted at over-50 consumers. NMN raises NAD+ availability upstream of the electron-transport chain; CoQ10 carries electrons within it. UK regulatory framing is different (NMN currently not authorised for sale in GB; CoQ10 is a lawful food supplement).
NMN (nicotinamide mononucleotide) is a precursor to NAD+, which donates electrons to Complex I of the electron-transport chain. CoQ10 then carries those electrons from Complex I to Complex III. The combination addresses different points in the same energy- metabolism pathway. Note: NMN is currently NOT authorised for sale in GB (FSA novel-food status pending) — Camden NB-161 ships under transparent-disclosure framing; see nmn.
Evidence: Combination has not been the subject of pivotal trials. Both ingredients individually have limited general-supplementation trial evidence.
Doses studied: NMN 250–500 mg + CoQ10 100 mg per serving in mitochondrial-support formulations targeted at over-50 consumers.